{"entity":{"id":"ncpe-ireland","kind":"institution","name":"National Centre for Pharmacoeconomics (NCPE), Ireland","aka":["NCPE"],"tldr":"Ireland's health technology assessment agency for medicines. Every new medicine seeking reimbursement gets a Rapid Review of about four weeks; costly or uncertain ones get a full assessment of about 18 weeks, and the HSE then decides.","summary":"The National Centre for Pharmacoeconomics describes itself as an independent health technology assessment agency responsible for evaluating drug treatments for the Irish healthcare system, assessing comparative effectiveness and cost-effectiveness. It is based at St James's Hospital, Dublin. The Health Service Executive is responsible for reimbursement decisions; its Corporate Pharmaceutical Unit commissions the NCPE to assess new active substances seeking reimbursement, including orphan medicines, and drugs already reimbursed that have high expenditure or uncertain benefit.\n\nAll medicines undergo a Rapid Review, which the NCPE aims to complete in about four weeks and which a company can submit at any point after a positive opinion from the European Medicines Agency's CHMP. Products with a high cost relative to comparators, a net impact on the drugs budget, or a question over comparative efficacy or value go to a full assessment, which takes about 18 weeks plus about five weeks while queries are with the company. For cancer medicines the full assessment report also goes to the National Cancer Control Programme. The HSE's decision criteria are set out in Schedule 3, Part 3 of the Health (Pricing and Supply of Medical Goods) Act 2013. Its home page carried a press release of 4 May 2026 on the first joint clinical assessment completed under the EU HTA Regulation. The coordinates are approximate.","asOf":"2026-11-11","links":[{"label":"NCPE: home page","url":"https://www.ncpe.ie/"},{"label":"NCPE: overview of the drug reimbursement process","url":"https://www.ncpe.ie/submission-process/overview-of-the-drug-reimbursement-process/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nccp-ireland","hpra-ireland"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Dublin","country":"IE","lat":53.343,"lng":-6.283,"institutionType":"government","website":"https://www.ncpe.ie","programs":["Rapid Review of new medicines","Full health technology assessment","Patient submissions to assessments","EU HTA Regulation joint clinical assessments"]},"route":"/institutions/ncpe-ireland/","neighbours":{"institution":[{"id":"hpra-ireland","kind":"institution","name":"Health Products Regulatory Authority (HPRA), Ireland","route":"/institutions/hpra-ireland/"},{"id":"nccp-ireland","kind":"institution","name":"National Cancer Control Programme (NCCP), HSE","route":"/institutions/nccp-ireland/"}]}}